Journal article icon

Journal article

Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes

Abstract:

Aims

This study evaluated the safety and efficacy of stereotactic radiation therapy (SRT) for the treatment of patients with oligometastases or oligorecurrence within mediastinal lymph nodes (MLNs) originating from different tumors.

Methods

Between October 2006 and May 2015, patients with MLN oligometastases or oligorecurrence were enrolled and treated with SRT at our hospital. The primary endpoint was MLN local control (LC). Secondary endpoints were time to symptom alleviation, overall survival (OS) after SRT, and toxicity using the Common Terminology Criteria for Adverse Events (CTCAE v4.0).

Results

Eighty-five patients with 98 MLN oligometastases or oligorecurrences were treated with SRT. For the entire cohort, the 1-year and 5-year actuarial LC rates were 97% and 77%, respectively. Of 53 symptomatic patients, symptom alleviation was observed in 47 (89%) after a median of 5 days (range, 3-30 days). The median OS was 27.2 months for all patients. For patients with non-small cell lung cancer, univariate and multivariate analyses revealed that a shorter interval between diagnosis of primary tumors and SRT and larger MLN SRT volume were associated with worse OS. CTCAE v4.0 ≥ Grade 3 toxicities occurred in six patients (7%), with Grade 5 in three patients (all with RT history to MLN station 7).

Conclusions

SRT is a safe and efficacious treatment modality for patients with oligometastases or oligorecurrence to MLNs originating from different tumors, except for patients who received radiotherapy to MLN station 7. Further investigation is warranted to identify the patients who benefit most from this treatment modality.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.18632/oncotarget.7636

Authors

More by this author
Role:
Author
ORCID:
0000-0002-4932-1986
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0001-8867-6635


Publisher:
Impact Journals
Journal:
Oncotarget More from this journal
Volume:
7
Issue:
14
Pages:
18135-18145
Publication date:
2016-02-23
DOI:
EISSN:
1949-2553
ISSN:
1949-2553


Language:
English
Keywords:
Pubs id:
2242214
Local pid:
pubs:2242214
Source identifiers:
W2282529162
Deposit date:
2026-04-23
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP